Dr Alejandra Sanchez and Charlie Dean consider the evolution of drug delivery technologies and how cell and gene therapies are showing promise as a new class of medicine to correct disease at its source.
Author profile
Alejandra Sanchez
Healthcare Business Developer
Alejandra is a biomedical engineer with a PhD in Biological Sciences and over five years of experience in product development, specialising in drug delivery and diagnostic devices. She has supported projects from early concept through to regulatory submission and market launch. Passionate about strategy and innovation, Alejandra enjoys advising clients and working at the forefront of deep tech.




